{"id": "round-20240202-142221-bb07d71a", "user_query": "\nRefer to the following files. Make sure to import the below modules in every code block you generate:\n\n\n\nThe below are the contents of the py files:\n\n\n## START OF CODEBLOCK \nPy Filename: c:\\Users\\selhousseini\\Documents\\GitHub\\mm-doc-analysis-rag-ce\\doc_ingestion_aidan\\Project_Atlas_-_CIM_-_pwd_Atlas2021.pdf\\text\\page_137.py\nPDF Filename: c:\\Users\\selhousseini\\Documents\\GitHub\\mm-doc-analysis-rag-ce\\doc_ingestion_aidan\\Project_Atlas_-_CIM_-_pwd_Atlas2021.pdf\\Project Atlas - CIM - pwd Atlas2021.pdf\nPDF Page: 137\n\nCode Block - Contents of the above Py file:\n```python\n\n# START OF CODE BLOCK 2c18f8ae\n\n# This code block contains variables capturing the operational expenditure (OPEX) breakdown for a company\n# from the years 2021 to 2025. The OPEX is adjusted for purchase frequency (PF) and is expressed in millions of euros (\u20acm).\n# The data includes expenses for Sales & Marketing (S&M), Research & Development (R&D), and Administration (Admin),\n# both for salaries/social expenses and other expenses. It also includes the total OPEX and average total headcount.\n# Additionally, the code block captures the percentage of total sales allocated to S&M, R&D, and Admin for each year.\n# The percentages are used to understand the distribution of sales spending across different departments.\n# The inflation rate for cost growth is also captured, as well as the expected increase in headcount for each department.\n\n# OPEX Breakdown (PF adjusted, \u20acm) for 2021\nvar_sm_salaries_2021_2c18f8ae = 7.3  # Sales & Marketing salaries and social expenses in 2021 (\u20acm)\nvar_sm_other_2021_2c18f8ae = 4.4  # Sales & Marketing other expenses in 2021 (\u20acm)\nvar_rd_salaries_2021_2c18f8ae = 2.3  # R&D salaries and social expenses in 2021 (\u20acm)\nvar_rd_other_2021_2c18f8ae = 1.0  # R&D other expenses in 2021 (\u20acm)\nvar_admin_salaries_2021_2c18f8ae = 3.2  # Administration salaries and social expenses in 2021 (\u20acm)\nvar_admin_other_2021_2c18f8ae = 0.9  # Administration other expenses in 2021 (\u20acm)\nvar_total_opex_2021_2c18f8ae = 19.2  # Total OPEX in 2021 (\u20acm)\nvar_avg_headcount_2021_2c18f8ae = 143  # Average total headcount in 2021\n\n# OPEX Breakdown (PF adjusted, \u20acm) for 2022\nvar_sm_salaries_2022_2c18f8ae = 8.0  # Sales & Marketing salaries and social expenses in 2022 (\u20acm)\nvar_sm_other_2022_2c18f8ae = 4.7  # Sales & Marketing other expenses in 2022 (\u20acm)\nvar_rd_salaries_2022_2c18f8ae = 2.5  # R&D salaries and social expenses in 2022 (\u20acm)\nvar_rd_other_2022_2c18f8ae = 1.2  # R&D other expenses in 2022 (\u20acm)\nvar_admin_salaries_2022_2c18f8ae = 3.4  # Administration salaries and social expenses in 2022 (\u20acm)\nvar_admin_other_2022_2c18f8ae = 0.9  # Administration other expenses in 2022 (\u20acm)\nvar_total_opex_2022_2c18f8ae = 20.8  # Total OPEX in 2022 (\u20acm)\nvar_avg_headcount_2022_2c18f8ae = 154  # Average total headcount in 2022\n\n# OPEX Breakdown (PF adjusted, \u20acm) for 2023\nvar_sm_salaries_2023_2c18f8ae = 8.6  # Sales & Marketing salaries and social expenses in 2023 (\u20acm)\nvar_sm_other_2023_2c18f8ae = 4.8  # Sales & Marketing other expenses in 2023 (\u20acm)\nvar_rd_salaries_2023_2c18f8ae = 2.6  # R&D salaries and social expenses in 2023 (\u20acm)\nvar_rd_other_2023_2c18f8ae = 1.3  # R&D other expenses in 2023 (\u20acm)\nvar_admin_salaries_2023_2c18f8ae = 3.6  # Administration salaries and social expenses in 2023 (\u20acm)\nvar_admin_other_2023_2c18f8ae = 0.9  # Administration other expenses in 2023 (\u20acm)\nvar_total_opex_2023_2c18f8ae = 21.9  # Total OPEX in 2023 (\u20acm)\nvar_avg_headcount_2023_2c18f8ae = 161  # Average total headcount in 2023\n\n# OPEX Breakdown (PF adjusted, \u20acm) for 2024\nvar_sm_salaries_2024_2c18f8ae = 9.0  # Sales & Marketing salaries and social expenses in 2024 (\u20acm)\nvar_sm_other_2024_2c18f8ae = 5.0  # Sales & Marketing other expenses in 2024 (\u20acm)\nvar_rd_salaries_2024_2c18f8ae = 2.8  # R&D salaries and social expenses in 2024 (\u20acm)\nvar_rd_other_2024_2c18f8ae = 1.3  # R&D other expenses in 2024 (\u20acm)\nvar_admin_salaries_2024_2c18f8ae = 3.8  # Administration salaries and social expenses in 2024 (\u20acm)\nvar_admin_other_2024_2c18f8ae = 0.9  # Administration other expenses in 2024 (\u20acm)\nvar_total_opex_2024_2c18f8ae = 22.8  # Total OPEX in 2024 (\u20acm)\nvar_avg_headcount_2024_2c18f8ae = 165  # Average total headcount in 2024\n\n# OPEX Breakdown (PF adjusted, \u20acm) for 2025\nvar_sm_salaries_2025_2c18f8ae = 9.3  # Sales & Marketing salaries and social expenses in 2025 (\u20acm)\nvar_sm_other_2025_2c18f8ae = 5.2  # Sales & Marketing other expenses in 2025 (\u20acm)\nvar_rd_salaries_2025_2c18f8ae = 2.9  # R&D salaries and social expenses in 2025 (\u20acm)\nvar_rd_other_2025_2c18f8ae = 1.3  # R&D other expenses in 2025 (\u20acm)\nvar_admin_salaries_2025_2c18f8ae = 4.0  # Administration salaries and social expenses in 2025 (\u20acm)\nvar_admin_other_2025_2c18f8ae = 1.0  # Administration other expenses in 2025 (\u20acm)\nvar_total_opex_2025_2c18f8ae = 23.7  # Total OPEX in 2025 (\u20acm)\nvar_avg_headcount_2025_2c18f8ae = 169  # Average total headcount in 2025\n\n# Percentage of total sales allocated to different departments\nvar_sales_percentage_sm_2021_2c18f8ae = 13.3  # Percentage of total sales for S&M in 2021\nvar_sales_percentage_rd_2021_2c18f8ae = 10.7  # Percentage of total sales for R&D in 2021\nvar_sales_percentage_admin_2021_2c18f8ae = 3.5  # Percentage of total sales for Admin in 2021\nvar_sales_percentage_total_2021_2c18f8ae = 21.9  # Total percentage of sales in 2021\n\n# Repeat for other years\nvar_sales_percentage_sm_2022_2c18f8ae = 3.8\nvar_sales_percentage_rd_2022_2c18f8ae = 12.8\nvar_sales_percentage_admin_2022_2c18f8ae = 3.1\nvar_sales_percentage_total_2022_2c18f8ae = 20.6\n\nvar_sales_percentage_sm_2023_2c18f8ae = 4.8\nvar_sales_percentage_rd_2023_2c18f8ae = 1.0\nvar_sales_percentage_admin_2023_2c18f8ae = 4.3\nvar_sales_percentage_total_2023_2c18f8ae = 20.8\n\nvar_sales_percentage_sm_2024_2c18f8ae = 12.6\nvar_sales_percentage_rd_2024_2c18f8ae = 3.7\nvar_sales_percentage_admin_2024_2c18f8ae = 4.3\nvar_sales_percentage_total_2024_2c18f8ae = 19.5\n\nvar_sales_percentage_sm_2025_2c18f8ae = 11.9\nvar_sales_percentage_rd_2025_2c18f8ae = 3.7\nvar_sales_percentage_admin_2025_2c18f8ae = 4.1\nvar_sales_percentage_total_2025_2c18f8ae = 17.6\n\n# Additional variables related to operational changes\nvar_inflation_rate_annual_2c18f8ae = 2.0  # Annual inflation rate for cost growth\nvar_additional_headcount_sm_2022_2c18f8ae = 5  # Additional S&M headcount in 2022\nvar_additional_headcount_sm_2023_2c18f8ae = 3  # Additional S&M headcount in 2023\nvar_additional_headcount_sm_2024_2c18f8ae = 1  # Additional S&M headcount in 2024\nvar_additional_headcount_sm_2025_2c18f8ae = 1  # Additional S&M headcount in 2025\nvar_additional_headcount_rd_annual_2c18f8ae = 1  # Additional R&D headcount added each year\nvar_additional_headcount_admin_annual_2c18f8ae = 1  # Additional Admin headcount added each year from 2022 to 2025\n\n# END OF CODE BLOCK 2c18f8ae\n\n```\n\nHere's the same data in Markdown format (if available):\n\n\n## END OF CODEBLOCK \n\n\n\n\n\n## START OF CODEBLOCK \nPy Filename: c:\\Users\\selhousseini\\Documents\\GitHub\\mm-doc-analysis-rag-ce\\doc_ingestion_aidan\\Intro_to_Aidian_Project_Atlas_15Jan2022.pdf\\text\\page_13.py\nPDF Filename: c:\\Users\\selhousseini\\Documents\\GitHub\\mm-doc-analysis-rag-ce\\doc_ingestion_aidan\\Intro_to_Aidian_Project_Atlas_15Jan2022.pdf\\Intro to Aidian Project Atlas 15Jan2022.pdf\nPDF Page: 13\n\nCode Block - Contents of the above Py file:\n```python\n\n# START OF CODE BLOCK c1add146\n\n# This code block captures the numerical data from a confidential document related to EW Healthcare Partners. \n# The document provides information about a non-binding bid, potential returns, trading updates, and sources & uses of funds.\n\n# Non-binding bid at an EV of c. \u20ac344M\nvar_bid_ev_euro_c1add146 = 344000000\n\n# Represents a 15x 2021E EBITDA of \u20ac22.9M\nvar_ebitda_multiple_c1add146 = 15\nvar_ebitda_2021_euro_c1add146 = 22900000\n\n# Assumes unitranche debt of \u20ac120M\nvar_unitranche_debt_euro_c1add146 = 120000000\n\n# Interest rate of 6.5% + EUROBOR\nvar_interest_rate_percentage_c1add146 = 6.5\n\n# Equity funding of \u20ac230M\nvar_equity_funding_euro_c1add146 = 230000000\n\n# Assumes MIP of 5%\nvar_mip_percentage_c1add146 = 5\n\n# Potential to generate 2.5x MOIC and IRR of 28%\nvar_potential_moic_c1add146 = 2.5\nvar_potential_irr_percentage_c1add146 = 28\n\n# END OF CODE BLOCK c1add146\n\n```\n\nHere's the same data in Markdown format (if available):\n\n| Variable Name | Value | Description |\n|---------------|-------|-------------|\n| var_bid_ev_euro_c1add146 | 344000000 | Non-binding bid at an EV of c. \u20ac344M |\n| var_ebitda_multiple_c1add146 | 15 | Represents a 15x 2021E EBITDA |\n| var_ebitda_2021_euro_c1add146 | 22900000 | 2021E EBITDA of \u20ac22.9M |\n| var_unitranche_debt_euro_c1add146 | 120000000 | Assumes unitranche debt of \u20ac120M |\n| var_interest_rate_percentage_c1add146 | 6.5 | Interest rate of 6.5% + EUROBOR |\n| var_equity_funding_euro_c1add146 | 230000000 | Equity funding of \u20ac230M |\n| var_mip_percentage_c1add146 | 5 | Assumes MIP of 5% |\n| var_potential_moic_c1add146 | 2.5 | Potential to generate 2.5x MOIC |\n| var_potential_irr_percentage_c1add146 | 28 | Potential to generate IRR of 28% |\n\n\n## END OF CODEBLOCK \n\n\n\n\n\n## START OF CODEBLOCK \nPy Filename: c:\\Users\\selhousseini\\Documents\\GitHub\\mm-doc-analysis-rag-ce\\doc_ingestion_aidan\\Intro_to_Aidian_Project_Atlas_15Jan2022.pdf\\text\\page_3.py\nPDF Filename: c:\\Users\\selhousseini\\Documents\\GitHub\\mm-doc-analysis-rag-ce\\doc_ingestion_aidan\\Intro_to_Aidian_Project_Atlas_15Jan2022.pdf\\Intro to Aidian Project Atlas 15Jan2022.pdf\nPDF Page: 3\n\nCode Block - Contents of the above Py file:\n```python\n\n# START OF CODE BLOCK acf00afa\n\n# The following variables represent numerical data extracted from an investment thesis for EW Healthcare Partners.\n# This data provides insights into market growth, financial profiles, and strategic opportunities for expansion and profitability.\n\n# var_market_growth_rate_acf00afa: The annual growth rate of the Point of Care (POC) In Vitro Diagnostics (IVD) market until 2025.\n# This rate is significant for projecting market size and potential revenue streams for companies operating in this segment.\nvar_market_growth_rate_acf00afa = 0.10\n\n# var_recurring_revenue_instruments_acf00afa: The number of installed instruments of the flagship QuickRead platform.\n# This number indicates the scale of the recurring revenue base and the market penetration of the product.\nvar_recurring_revenue_instruments_acf00afa = 60000\n\n# var_cash_conversion_rate_acf00afa: The percentage of cash conversion, indicating the efficiency of the company's operations\n# in turning profits into cash flow. A high rate suggests strong operational health and financial stability.\nvar_cash_conversion_rate_acf00afa = 0.90\n\n# var_potential_returns_multiple_acf00afa: The potential multiple of returns on investment within a hold period of 3-4 years.\n# This figure is used for investment appraisal and to set expectations for financial returns.\nvar_potential_returns_multiple_acf00afa = 2.5\n\n# var_hold_period_years_acf00afa: The expected hold period in years for the investment to potentially generate the targeted returns.\n# This duration is crucial for investment strategies and exit planning.\nvar_hold_period_years_acf00afa = 3.5  # Average of 3-4 years\n\n# var_mna_targets_acf00afa: The number of targets on the M&A shortlist, indicating the scope of potential acquisition opportunities.\n# This number helps in understanding the scale of expansion and strategic options available.\nvar_mna_targets_acf00afa = 80\n\n# END OF CODE BLOCK acf00afa\n\n```\n\nHere's the same data in Markdown format (if available):\n\n| Variable Name                             | Description                                                                                   | Value  |\n|-------------------------------------------|-----------------------------------------------------------------------------------------------|--------|\n| `var_market_growth_rate_acf00afa`         | Annual growth rate of the POC IVD market until 2025                                           | 0.10   |\n| `var_recurring_revenue_instruments_acf00afa` | Number of installed instruments of the flagship QuickRead platform                           | 60000  |\n| `var_cash_conversion_rate_acf00afa`      | Percentage of cash conversion indicating operational efficiency                               | 0.90   |\n| `var_potential_returns_multiple_acf00afa` | Potential multiple of returns on investment within a hold period of 3-4 years                | 2.5    |\n| `var_hold_period_years_acf00afa`         | Expected hold period in years for the investment                                              | 3.5    |\n| `var_mna_targets_acf00afa`               | Number of targets on the M&A shortlist                                                        | 80     |\n\n\n## END OF CODEBLOCK \n\n\n\n\n\n## START OF CODEBLOCK \nPy Filename: c:\\Users\\selhousseini\\Documents\\GitHub\\mm-doc-analysis-rag-ce\\doc_ingestion_aidan\\Intro_to_Aidian_Project_Atlas_15Jan2022.pdf\\text\\page_12.py\nPDF Filename: c:\\Users\\selhousseini\\Documents\\GitHub\\mm-doc-analysis-rag-ce\\doc_ingestion_aidan\\Intro_to_Aidian_Project_Atlas_15Jan2022.pdf\\Intro to Aidian Project Atlas 15Jan2022.pdf\nPDF Page: 12\n\nCode Block - Contents of the above Py file:\n```python\n\n```\n\nHere's the same data in Markdown format (if available):\n\n\n## END OF CODEBLOCK \n\n\n\n\n\n## START OF CODEBLOCK \nPy Filename: c:\\Users\\selhousseini\\Documents\\GitHub\\mm-doc-analysis-rag-ce\\doc_ingestion_aidan\\Intro_to_Aidian_Project_Atlas_15Jan2022.pdf\\text\\page_2.py\nPDF Filename: c:\\Users\\selhousseini\\Documents\\GitHub\\mm-doc-analysis-rag-ce\\doc_ingestion_aidan\\Intro_to_Aidian_Project_Atlas_15Jan2022.pdf\\Intro to Aidian Project Atlas 15Jan2022.pdf\nPDF Page: 2\n\nCode Block - Contents of the above Py file:\n```python\n\n# START OF CODE BLOCK b35c0b9b\n\n# This code block captures the financial and operational data of Aidian Oy, a Finland-based in-vitro diagnostics company. \n# The data includes expected sales, EBITDA, growth rate, and the indicative bid for the company. \n# The data is expected to be used for financial analysis and decision-making purposes.\n\n# Expected sales of Aidian Oy in 2021 in Euros\nvar_expected_sales_2021_b35c0b9b = 94.6e6 # Euros\n\n# EBITDA of Aidian Oy in 2021 in Euros\nvar_EBITDA_2021_b35c0b9b = 22.9e6 # Euros\n\n# Year-on-year growth rate of Aidian Oy in 2021\nvar_growth_rate_2021_b35c0b9b = 33 # Percentage\n\n# Indicative bid for Aidian Oy based on 2021E EBITDA\nvar_indicative_bid_b35c0b9b = 15 # Times EBITDA\n\n# Implied Enterprise Value of Aidian Oy based on the indicative bid\nvar_EV_b35c0b9b = 344e6 # Euros\n\n# Assumed debt financing for the acquisition of Aidian Oy\nvar_debt_financing_b35c0b9b = 120e6 # Euros\n\n# END OF CODE BLOCK b35c0b9b\n\n```\n\nHere's the same data in Markdown format (if available):\n\n\n## END OF CODEBLOCK \n\n\n\n\n\n## START OF CODEBLOCK \nPy Filename: c:\\Users\\selhousseini\\Documents\\GitHub\\mm-doc-analysis-rag-ce\\doc_ingestion_aidan\\Project_Atlas_-_CIM_-_pwd_Atlas2021.pdf\\text\\page_9.py\nPDF Filename: c:\\Users\\selhousseini\\Documents\\GitHub\\mm-doc-analysis-rag-ce\\doc_ingestion_aidan\\Project_Atlas_-_CIM_-_pwd_Atlas2021.pdf\\Project Atlas - CIM - pwd Atlas2021.pdf\nPDF Page: 9\n\nCode Block - Contents of the above Py file:\n```python\n\n# START OF CODE BLOCK 602e4651\n\n# The underlying non-cyclical POC IVD market is expected to grow by 10% year-on-year between 2021 and 2025.\nvar_market_growth_rate_602e4651 = 10\n\n# The installed base of QuikRead instruments sold worldwide is 60k.\nvar_quikread_instruments_sold_602e4651 = 60000\n\n# The direct sales model is used in 12 European countries, which accounts for 85% of sales.\nvar_direct_sales_countries_602e4651 = 12\nvar_direct_sales_percentage_602e4651 = 85\n\n# The distributor network enables a global reach in 70 countries.\nvar_distributor_network_countries_602e4651 = 70\n\n# The razorblade business model has approximately 90% recurring test revenue for the QuikRead platform.\nvar_recurring_test_revenue_percentage_602e4651 = 90\n\n# The gross margin and EBITDA margin for the QuikRead platform are approximately 45% and 20% respectively.\nvar_gross_margin_percentage_602e4651 = 45\nvar_EBITDA_margin_percentage_602e4651 = 20\n\n# The sales CAGR in direct sales markets since 2018 is 28%.\nvar_sales_CAGR_percentage_602e4651 = 28\n\n# END OF CODE BLOCK 602e4651\n\n```\n\nHere's the same data in Markdown format (if available):\n\n| Variable Name | Description |\n| --- | --- |\n| var_market_growth_rate_602e4651 | The underlying non-cyclical POC IVD market is expected to grow by 10% year-on-year between 2021 and 2025. |\n| var_quikread_instruments_sold_602e4651 | The installed base of QuikRead instruments sold worldwide is 60k. |\n| var_direct_sales_countries_602e4651 | The direct sales model is used in 12 European countries. |\n| var_direct_sales_percentage_602e4651 | The direct sales model accounts for 85% of sales. |\n| var_distributor_network_countries_602e4651 | The distributor network enables a global reach in 70 countries. |\n| var_recurring_test_revenue_percentage_602e4651 | The razorblade business model has approximately 90% recurring test revenue for the QuikRead platform. |\n| var_gross_margin_percentage_602e4651 | The gross margin for the QuikRead platform is approximately 45%. |\n| var_EBITDA_margin_percentage_602e4651 | The EBITDA margin for the QuikRead platform is approximately 20%. |\n| var_sales_CAGR_percentage_602e4651 | The sales CAGR in direct sales markets since 2018 is 28%. |\n\n\n## END OF CODEBLOCK \n\n\n\n\n\n## START OF CODEBLOCK \nPy Filename: c:\\Users\\selhousseini\\Documents\\GitHub\\mm-doc-analysis-rag-ce\\doc_ingestion_aidan\\Case_Study_#4_-_Comps.pdf\\tables\\page_1_table_0.py\nPDF Filename: c:\\Users\\selhousseini\\Documents\\GitHub\\mm-doc-analysis-rag-ce\\doc_ingestion_aidan\\Case_Study_#4_-_Comps.pdf\\Case Study #4 - Comps.pdf\nPDF Page: 1\n\nCode Block - Contents of the above Py file:\n```python\nimport pandas as pd\n\n# Unique dataframe name as per instructions\ndf_public_trading_comps_123456 = pd.DataFrame({\n    'Company Name': ['Roche', 'Abbott', 'Danaher', 'Becton, Dickinson', 'Sysmex', 'Hologic', 'Biomerieux', 'Diasorin', 'Tecan', 'Quidel', 'Ortho Clinical Diagnostics', 'Stratec', 'EKF Diagnostics', 'Mean', 'Median', 'Aidian - Mgmt Case'],\n    'Mkt Cap': ['\u20ac 281,994', '\u20ac 190,266', '\u20ac 176,695', '\u20ac 66,508', '\u20ac 18,204', '\u20ac 15,650', '\u20ac 12,035', '\u20ac 7,817', '\u20ac 5,497', '\u20ac 3,859', '\u20ac 3,754', '\u20ac 1,448', '\u20ac 400', '\u20ac', '\u20ac', '\u20ac'],\n    'EV': ['\u20ac 293,435', '\u20ac 198,132', '\u20ac 199,048', '\u20ac 80,427', '\u20ac 17,759', '\u20ac 17,397', '\u20ac 12,117', '\u20ac 8,973', '\u20ac 5,013', '\u20ac 3,474', '\u20ac 5,570', '\u20ac 1,492', '\u20ac 378', '\u20ac', '\u20ac', '\u20ac 99'],\n    'Revenue': ['\u20ac 56,648', '\u20ac 36,503', '\u20ac 24,209', '\u20ac 17,470', '\u20ac 2,643', '\u20ac 4,810', '\u20ac 3,216', '\u20ac 1,310', '\u20ac 798', '\u20ac 1,614', '\u20ac 1,758', '\u20ac 296', '\u20ac 90', '\u20ac', '\u20ac', '\u20ac'],\n    'Revenue CAGR 18-21E': ['4.4%', '11.6%', '20.0%', '3.9%', '3.8%', '13.5%', '11.4%', '22.2%', '20.2%', '44.4%', '4.8%', '15.3%', '25.0%', '15.4%', '13.5%', '20.8%'],\n    'Revenue CAGR 21-23E': ['2.1%', '10.0%', '5.8%', '4.7%', '3.2%', '7.2%', '2.8%', '6.7%', '8.2%', '33.0%', '8.3%', '8.2%', '3.9%', '1.3%', '3.4%', '9.5%'],\n    'Gross Margin': ['72.3%', '56.8%', '60.7%', '47.8%', '51.7%', '72.3%', '67.5%', '50.6%', '49.5%', '79.3%', '24.4%', '29.7%', '32.2%', '57.1%', '56.8%', '42.7%'],\n    'EBITDA Margin': ['37.6%', '28.2%', '34.4%', '27.9%', '27.0%', '51.3%', '27.7%', '23.0%', '22.4%', '34.3%', '12.4%', '22.4%', '32.4%', '34.1%', '29.2%', '23.1%'],\n    'LTM': ['12.8x', '17.7x', '22.7x', '15.8x', '25.9x', '6.8x', '13.2x', '18.5x', '25.1x', '3.5x', '11.8x', '21.8x', '12.4x', '17.1x', '16.7x', '15.0x'],\n    'NTM': ['11.8x', '19.1x', '22.0x', '16.6x', '22.3x', '13.9x', '13.2x', '19.2x', '22.4x', '7.0x', '11.6x', '19.8x', '12.1x', '17.0x', '17.9x', '12.7x'],\n    '23E': ['11.2x', '17.8x', '20.4x', '15.2x', '19.7x', '13.4x', '13.7x', '19.2x', '19.2x', '23.0x', '10.6x', '17.9x', '11.3x', '15.8x', '16.5x', '11.8x'],\n    'Cash Conv.': ['84.3%', '84.3%', '87.7%', '78.2%', '89.2%', '94.6%', '67.1%', '95.3%', '85.4%', '75.9%', '91.3%', '81.7%', '92.9%', '85.2%', '85.4%', '96.1%'],\n    'LFCF Yield LTM': ['5.3%', '3.3%', '3.3%', '5.6%', '4.3%', '9.6%', '2.1%', '4.5%', '3.1%', '14.7%', '7.8%', '2.3%', '2.8%', '4.3%', '4.4%', '4.0%']\n})\n\n# Display the dataframe\nprint(df_public_trading_comps_123456)\n```\n\nHere's the same data in Markdown format (if available):\n\n| Company Name         | Mkt Cap | EV     | Revenue | Revenue CAGR | LTM Margin % | EV/EBITDA | Cash Conv. | LFCF Yield |\n|----------------------|---------|--------|---------|--------------|--------------|-----------|-------------|------------|\n|                      |         |        | 18'-21E | 21E-23E Gross| LTM  | NTM  | LTM  | LTM         | LTM         |\n|                      | (\u20ac m)   | (\u20ac m)  | (\u20ac m)   |              | Gross| EBITDA| 23E  |             |             |\n| Roche                | 281,994 | 293,435| 56,648  | 4.4%         | 72.3%| 37.6% | 12.8x| 11.8x       | 5.3%        |\n| Abbott               | 190,266 | 198,132| 36,503  | 11.6%        | 58.6%| 28.2% | 17.7x| 19.1x       | 5.3%        |\n| Danaher              | 176,695 | 199,048| 24,209  | 20.0%        | 60.7%| 34.4% | 22.7x| 22.0x       | 3.3%        |\n| Becton, Dickinson    | 66,508  | 80,427 | 17,470  | 3.9%         | 48.7%| 27.9% | 15.8x| 16.6x       | 5.6%        |\n| Sysmex               | 18,204  | 17,759 | 2,643   | 3.8%         | 51.7%| 27.0% | 25.9x| 22.3x       | 4.3%        |\n| Hologic              | 15,650  | 17,397 | 4,810   | 13.5%        | 72.3%| 51.3% | 6.8x | 13.9x       | 9.6%        |\n| Biomerieux           | 12,035  | 12,117 | 3,316   | 11.4%        | 67.5%| 27.7% | 13.2x| 13.2x       | 2.1%        |\n| Diasorin             | 7,817   | 8,973  | 1,210   | 22.2%        | 80.6%| 43.0% | 18.8x| 19.1x       | 4.5%        |\n| Tecan                | 5,497   | 5,013  | 798     | 20.2%        | 49.5%| 22.4% | 25.1x| 22.4x       | 3.1%        |\n| Quidel               | 3,859   | 3,474  | 1,614   | 44.4%        | 79.3%| 64.3% | 3.5x | 7.0x        | 14.7%        |\n| Ortho Clinical Diagnostics | 3,754 | 5,570 | 1,758 | 4.8%       | 49.1%| 24.2% | 11.8x| 11.6x       | 7.8%        |\n| Stratec              | 1,448   | 1,492  | 296     | 15.3%        | 52.8%| 22.4% | 21.8x| 19.8x       | 2.3%        |\n| EKF Diagnostics      | 400     | 378    | 90      | 25.0%        | 53.9%| 32.2% | 12.4x| 12.1x       | 2.8%        |\n| **Mean**             |         |        |         | 15.4%        | 57.3%| 34.1% | 17.1x| 17.0x       | 4.3%        |\n| **Median**           |         |        |         | 13.5%        | 54.6%| 28.9% | 16.7x| 17.9x       | 4.4%        |\n| **Aidian - Mgmt Case** |       |        |         | 20.8%        | 42.7%| 23.1% | 15.0x| 12.7x       | 4.0%        |\n\n\n## END OF CODEBLOCK \n\n\n\n\n\n## START OF CODEBLOCK \nPy Filename: c:\\Users\\selhousseini\\Documents\\GitHub\\mm-doc-analysis-rag-ce\\doc_ingestion_aidan\\Case_Study_#4_-_Comps.pdf\\images\\page_1_image_2.py\nPDF Filename: c:\\Users\\selhousseini\\Documents\\GitHub\\mm-doc-analysis-rag-ce\\doc_ingestion_aidan\\Case_Study_#4_-_Comps.pdf\\Case Study #4 - Comps.pdf\nPDF Page: 1\n\nCode Block - Contents of the above Py file:\n```python\n\nimport pandas as pd\n\ndata = {\n    'Company Name': ['Roche', 'Abbott', 'Danaher', 'Becton, Dickinson', 'Sysmex', 'Hologic', 'Biomerieux', 'Diasorin', 'Tecan', 'Quidel', 'Ortho Clinical Diagnostics', 'Stratec', 'EKF Diagnostics', 'Mean', 'Median', 'Aidian - Mgmt Case'],\n    'Mkt Cap': ['\u20ac281,994', '\u20ac190,266', '\u20ac176,695', '\u20ac66,508', '\u20ac18,204', '\u20ac15,650', '\u20ac12,035', '\u20ac7,817', '\u20ac5,497', '\u20ac3,859', '\u20ac3,754', '\u20ac1,448', '\u20ac400', '', '', ''],\n    'EV': ['\u20ac293,435', '\u20ac198,132', '\u20ac199,048', '\u20ac80,427', '\u20ac17,759', '\u20ac17,397', '\u20ac12,117', '\u20ac8,973', '\u20ac5,013', '\u20ac3,474', '\u20ac5,570', '\u20ac1,492', '\u20ac378', '', '', ''],\n    'Revenue': ['\u20ac56,648', '\u20ac36,503', '\u20ac24,209', '\u20ac17,470', '\u20ac2,643', '\u20ac4,810', '\u20ac3,126', '\u20ac1,310', '\u20ac798', '\u20ac1,614', '\u20ac1,758', '\u20ac296', '\u20ac90', '', '', '99'],\n    # ... (other columns follow the same pattern)\n}\n\ndf_public_trading_comps_3927364 = pd.DataFrame(data)\n\n```\n\nHere's the same data in Markdown format (if available):\n\n| Company Name                | Mkt Cap | EV     | Revenue | Revenue CAGR 18'-21'E | Revenue CAGR 21'E-23'E | LTM Margin % Gross | LTM Margin % EBITDA | EV/EBITDA LTM | EV/EBITDA NTM | EV/EBITDA 23E | Cash Conv. LFCF Yield LTM | Cash Conv. LFCF Yield LTM |\n|-----------------------------|---------|--------|---------|-----------------------|------------------------|--------------------|---------------------|---------------|---------------|---------------|---------------------------|---------------------------|\n| Roche                       | \u20ac281,994| \u20ac293,435| \u20ac56,648 | 4.4%                  | 72.3%                  | 37.6%              | 12.8x               | 11.8x         | 11.2x         | 84.3%                     | 5.3%                      |\n| Abbott                      | \u20ac190,266| \u20ac198,132| \u20ac36,503 | 11.6%                 | 56.8%                  | 29.5%              | 17.7x               | 19.1x         | 17.8x         | 84.3%                     | 5.3%                      |\n| ...                         | ...     | ...    | ...     | ...                   | ...                    | ...                | ...                 | ...           | ...           | ...                       | ...                       |\n| Mean                        |         |        |         | 15.4%                 | 57.3%                  | 34.1%              | 17.1x               | 17.0x         | 15.8x         | 85.2%                     | 4.3%                      |\n| Median                      |         |        |         | 13.5%                 | 54.6%                  | 29.2%              | 16.7x               | 17.9x         | 16.5x         | 85.4%                     | 4.4%                      |\n| Aidian - Mgmt Case          |         |        | 99      | 20.8%                 | 9.5%                   | 42.7%              | 23.1%               | 15.0x         | 12.7x         | 11.8x                     | 96.1%                     | 4.0%                      |\n\n\n## END OF CODEBLOCK \n\n\n\n\n\n## START OF CODEBLOCK \nPy Filename: c:\\Users\\selhousseini\\Documents\\GitHub\\mm-doc-analysis-rag-ce\\doc_ingestion_aidan\\Case_Study_#4_-_Comps.pdf\\text\\page_1.py\nPDF Filename: c:\\Users\\selhousseini\\Documents\\GitHub\\mm-doc-analysis-rag-ce\\doc_ingestion_aidan\\Case_Study_#4_-_Comps.pdf\\Case Study #4 - Comps.pdf\nPDF Page: 1\n\nCode Block - Contents of the above Py file:\n```python\n\n# START OF CODE BLOCK d5e28541\n\n# There are no numerical quantities in the TEXT EXTRACT to declare as variables.\n\n# END OF CODE BLOCK d5e28541\n\n```\n\nHere's the same data in Markdown format (if available):\n\nThere are no numerical data quantities in the TEXT EXTRACT to represent in a Markdown table.\n\n\n## END OF CODEBLOCK \n\n\n\n\n\n## START OF CODEBLOCK \nPy Filename: c:\\Users\\selhousseini\\Documents\\GitHub\\mm-doc-analysis-rag-ce\\doc_ingestion_aidan\\Case_Study_#4_-_Comps.pdf\\text\\page_2.py\nPDF Filename: c:\\Users\\selhousseini\\Documents\\GitHub\\mm-doc-analysis-rag-ce\\doc_ingestion_aidan\\Case_Study_#4_-_Comps.pdf\\Case Study #4 - Comps.pdf\nPDF Page: 2\n\nCode Block - Contents of the above Py file:\n```python\n\n```\n\nHere's the same data in Markdown format (if available):\n\n\n## END OF CODEBLOCK \n\n\n\n\n\n## START OF CODEBLOCK \nPy Filename: c:\\Users\\selhousseini\\Documents\\GitHub\\mm-doc-analysis-rag-ce\\doc_ingestion_aidan\\Project_Atlas_-_CIM_-_pwd_Atlas2021.pdf\\text\\page_106.py\nPDF Filename: c:\\Users\\selhousseini\\Documents\\GitHub\\mm-doc-analysis-rag-ce\\doc_ingestion_aidan\\Project_Atlas_-_CIM_-_pwd_Atlas2021.pdf\\Project Atlas - CIM - pwd Atlas2021.pdf\nPDF Page: 106\n\nCode Block - Contents of the above Py file:\n```python\n\n# START OF CODE BLOCK 1d4a9fee\n\n# This code block contains variables that capture key numerical data points from a confidential text extract\n# regarding the monetisation strategies for the SIBA technology platform. The variables are intended to be used\n# by other Python programs that may need to reference or analyze these strategies and their potential impacts.\n# The text extract discusses various pathways for monetisation, including outlicensing, co-development, point-of-care\n# (POC) medical diagnostics (MDx) strategy, and instrument-free SIBA development. It also mentions the potential\n# for entering the US market, leveraging existing customer groups, and building an intellectual property (IP) portfolio.\n# The extract includes an executive summary that covers market overview, product portfolio, group operations,\n# strategic growth levers, financial overview, and conclusions. Additionally, it touches on cost optimisation,\n# mergers and acquisitions (M&A), US expansion, organic growth, China market, the SIBA platform, and EW Healthcare.\n\n# Note: The TEXT EXTRACT does not contain explicit numerical data. Therefore, no variables are declared.\n# The following is a placeholder for the structure of the code block in case numerical data were present.\n\n# Example of a variable declaration if numerical data were present:\n# var_example_numerical_data_1d4a9fee = 0  # This variable would represent an example numerical data point from the text extract.\n\n# END OF CODE BLOCK 1d4a9fee\n\n```\n\nHere's the same data in Markdown format (if available):\n\n| Variable Name | Purpose | Context | Source |\n|---------------|---------|---------|--------|\n|               |         |         |        |\n\n\n## END OF CODEBLOCK \n\n\n\n\nDo **NOT** forget to import the below py modules in every new code block you generate:\n# Import the list of Python files specified by the user\nList of Python Files:\n## START OF LIST OF PYTHON FILES TO IMPORT\n\n## END OF LIST OF PYTHON FILES TO IMPORT\n\nHere is the Chain of Thought and the step-by-step that you should follow:\n\n    1. Please analyze the question first, and locate the variables of interests in the question. For each variable, try to locate the relevant dataframes in the Codeblocks above (delimited by '## START OF CODEBLOCK' and '## END OF CODEBLOCK') and the relevant variable assignment statements.\n    2. You **MUST** import the list of Python files specified by the user above in the \"List of Python Files\" section.\n    3. Use the Codeblocks delimited by '## START OF CODEBLOCK' and '## END OF CODEBLOCK' to identify and print to the output the variables of interest. Include the variable assignment statements in the output. Limit this list to the relevant variables **ONLY**. Generate the Python code that will do this step and execute it.\n    4. Use the Codeblocks delimited by '## START OF CODEBLOCK' and '## END OF CODEBLOCK' to identify and print to the output the relevant dataframes names, and print to the output all their columns. Also print all the variable assignment statements. Include the dataframes assignment statements in the output. Limit this list to the relevant dataframes **ONLY**. Generate the Python code that will do this step and execute it.\n    5. If you have trouble accessing the previously defined variables or the dataframes for any reasons, then use the Python Codeblocks delimited by '## START OF CODEBLOCK' and '## END OF CODEBLOCK' to extract the information you need, and then generate the needed Python code.\n    6. Generate the answer to the query. You **MUST** clarify AND print to the output **ALL** calculation steps leading up to the final answer.\n    7. You **MUST** detail how you came up with the answer. Please provide a complete description of the calculation steps taken to get to the answer. Please reference the PDF Document and the page number you got the answer from, e.g. \"This answer was derived from document 'Sales_Presentation.pdf', page 34\".\n    8. If the answer contains numerical data, then you **MUST** create an Excel file with an extension .xlsx with the data, you **MUST** include inside the Excel the steps of the calculations, the justification, and **ALL** the reference and source numbers and tables that you used to come up with a final answer in addition to the final answer (this Excel is meant for human consumption, do **NOT** use programming variable names as column or row headers, instead use names that are fully meaningful to humans), you **MUST** be elaborate in your comments and rows and column names inside the Excel, you **MUST** save it to the working directory, and then you **MUST** print the full path of the Excel sheet with the final answer - use os.path.abs() to print the full path.\n    9. **VERY IMPORTANT**: do **NOT** attempt to create a list of variables or dataframes directly. Instead, you should access the data from the variables and dataframes that were defined in the Python file that was run.\n    \n\nQuestion: is it good option to invest in this company?\n\nIn your final answer, be elaborate in your response. Describe your logic and the calculation steps to the user, and describe how you deduced the answer step by step. If there are any assumptions you made, please state them clearly. Describe in details the computation steps you took, quote values and quantities, describe equations as if you are explaining a solution of a math problem to a 12-year old student. Please relay all steps to the user, and clarify how you got to the final answer. Please reference the PDF Document and the page number you got the answer from, e.g. \"This answer was derived from document 'Sales_Presentation.pdf', page 34\". After generating the final response, and if the final answer contains numerical data, then you **MUST** create an Excel file with an extension .xlsx with the data, you **MUST** include inside the Excel the steps of the calculations, the justification, and **ALL** the reference and source numbers and tables that you used to come up with a final answer in addition to the final answer (this Excel is meant for human consumption, do **NOT** use programming variable names as column or row headers, instead use names that are fully meaningful to humans), you **MUST** be elaborate in your comments and rows and column names inside the Excel, you **MUST** save it to the working directory, and then you **MUST** print the full path of the Excel sheet with the final answer - use os.path.abs() to print the full path.\n\n", "state": "failed", "post_list": [{"id": "post-20240202-142221-43ccde2f", "message": "\nRefer to the following files. Make sure to import the below modules in every code block you generate:\n\n\n\nThe below are the contents of the py files:\n\n\n## START OF CODEBLOCK \nPy Filename: c:\\Users\\selhousseini\\Documents\\GitHub\\mm-doc-analysis-rag-ce\\doc_ingestion_aidan\\Project_Atlas_-_CIM_-_pwd_Atlas2021.pdf\\text\\page_137.py\nPDF Filename: c:\\Users\\selhousseini\\Documents\\GitHub\\mm-doc-analysis-rag-ce\\doc_ingestion_aidan\\Project_Atlas_-_CIM_-_pwd_Atlas2021.pdf\\Project Atlas - CIM - pwd Atlas2021.pdf\nPDF Page: 137\n\nCode Block - Contents of the above Py file:\n```python\n\n# START OF CODE BLOCK 2c18f8ae\n\n# This code block contains variables capturing the operational expenditure (OPEX) breakdown for a company\n# from the years 2021 to 2025. The OPEX is adjusted for purchase frequency (PF) and is expressed in millions of euros (\u20acm).\n# The data includes expenses for Sales & Marketing (S&M), Research & Development (R&D), and Administration (Admin),\n# both for salaries/social expenses and other expenses. It also includes the total OPEX and average total headcount.\n# Additionally, the code block captures the percentage of total sales allocated to S&M, R&D, and Admin for each year.\n# The percentages are used to understand the distribution of sales spending across different departments.\n# The inflation rate for cost growth is also captured, as well as the expected increase in headcount for each department.\n\n# OPEX Breakdown (PF adjusted, \u20acm) for 2021\nvar_sm_salaries_2021_2c18f8ae = 7.3  # Sales & Marketing salaries and social expenses in 2021 (\u20acm)\nvar_sm_other_2021_2c18f8ae = 4.4  # Sales & Marketing other expenses in 2021 (\u20acm)\nvar_rd_salaries_2021_2c18f8ae = 2.3  # R&D salaries and social expenses in 2021 (\u20acm)\nvar_rd_other_2021_2c18f8ae = 1.0  # R&D other expenses in 2021 (\u20acm)\nvar_admin_salaries_2021_2c18f8ae = 3.2  # Administration salaries and social expenses in 2021 (\u20acm)\nvar_admin_other_2021_2c18f8ae = 0.9  # Administration other expenses in 2021 (\u20acm)\nvar_total_opex_2021_2c18f8ae = 19.2  # Total OPEX in 2021 (\u20acm)\nvar_avg_headcount_2021_2c18f8ae = 143  # Average total headcount in 2021\n\n# OPEX Breakdown (PF adjusted, \u20acm) for 2022\nvar_sm_salaries_2022_2c18f8ae = 8.0  # Sales & Marketing salaries and social expenses in 2022 (\u20acm)\nvar_sm_other_2022_2c18f8ae = 4.7  # Sales & Marketing other expenses in 2022 (\u20acm)\nvar_rd_salaries_2022_2c18f8ae = 2.5  # R&D salaries and social expenses in 2022 (\u20acm)\nvar_rd_other_2022_2c18f8ae = 1.2  # R&D other expenses in 2022 (\u20acm)\nvar_admin_salaries_2022_2c18f8ae = 3.4  # Administration salaries and social expenses in 2022 (\u20acm)\nvar_admin_other_2022_2c18f8ae = 0.9  # Administration other expenses in 2022 (\u20acm)\nvar_total_opex_2022_2c18f8ae = 20.8  # Total OPEX in 2022 (\u20acm)\nvar_avg_headcount_2022_2c18f8ae = 154  # Average total headcount in 2022\n\n# OPEX Breakdown (PF adjusted, \u20acm) for 2023\nvar_sm_salaries_2023_2c18f8ae = 8.6  # Sales & Marketing salaries and social expenses in 2023 (\u20acm)\nvar_sm_other_2023_2c18f8ae = 4.8  # Sales & Marketing other expenses in 2023 (\u20acm)\nvar_rd_salaries_2023_2c18f8ae = 2.6  # R&D salaries and social expenses in 2023 (\u20acm)\nvar_rd_other_2023_2c18f8ae = 1.3  # R&D other expenses in 2023 (\u20acm)\nvar_admin_salaries_2023_2c18f8ae = 3.6  # Administration salaries and social expenses in 2023 (\u20acm)\nvar_admin_other_2023_2c18f8ae = 0.9  # Administration other expenses in 2023 (\u20acm)\nvar_total_opex_2023_2c18f8ae = 21.9  # Total OPEX in 2023 (\u20acm)\nvar_avg_headcount_2023_2c18f8ae = 161  # Average total headcount in 2023\n\n# OPEX Breakdown (PF adjusted, \u20acm) for 2024\nvar_sm_salaries_2024_2c18f8ae = 9.0  # Sales & Marketing salaries and social expenses in 2024 (\u20acm)\nvar_sm_other_2024_2c18f8ae = 5.0  # Sales & Marketing other expenses in 2024 (\u20acm)\nvar_rd_salaries_2024_2c18f8ae = 2.8  # R&D salaries and social expenses in 2024 (\u20acm)\nvar_rd_other_2024_2c18f8ae = 1.3  # R&D other expenses in 2024 (\u20acm)\nvar_admin_salaries_2024_2c18f8ae = 3.8  # Administration salaries and social expenses in 2024 (\u20acm)\nvar_admin_other_2024_2c18f8ae = 0.9  # Administration other expenses in 2024 (\u20acm)\nvar_total_opex_2024_2c18f8ae = 22.8  # Total OPEX in 2024 (\u20acm)\nvar_avg_headcount_2024_2c18f8ae = 165  # Average total headcount in 2024\n\n# OPEX Breakdown (PF adjusted, \u20acm) for 2025\nvar_sm_salaries_2025_2c18f8ae = 9.3  # Sales & Marketing salaries and social expenses in 2025 (\u20acm)\nvar_sm_other_2025_2c18f8ae = 5.2  # Sales & Marketing other expenses in 2025 (\u20acm)\nvar_rd_salaries_2025_2c18f8ae = 2.9  # R&D salaries and social expenses in 2025 (\u20acm)\nvar_rd_other_2025_2c18f8ae = 1.3  # R&D other expenses in 2025 (\u20acm)\nvar_admin_salaries_2025_2c18f8ae = 4.0  # Administration salaries and social expenses in 2025 (\u20acm)\nvar_admin_other_2025_2c18f8ae = 1.0  # Administration other expenses in 2025 (\u20acm)\nvar_total_opex_2025_2c18f8ae = 23.7  # Total OPEX in 2025 (\u20acm)\nvar_avg_headcount_2025_2c18f8ae = 169  # Average total headcount in 2025\n\n# Percentage of total sales allocated to different departments\nvar_sales_percentage_sm_2021_2c18f8ae = 13.3  # Percentage of total sales for S&M in 2021\nvar_sales_percentage_rd_2021_2c18f8ae = 10.7  # Percentage of total sales for R&D in 2021\nvar_sales_percentage_admin_2021_2c18f8ae = 3.5  # Percentage of total sales for Admin in 2021\nvar_sales_percentage_total_2021_2c18f8ae = 21.9  # Total percentage of sales in 2021\n\n# Repeat for other years\nvar_sales_percentage_sm_2022_2c18f8ae = 3.8\nvar_sales_percentage_rd_2022_2c18f8ae = 12.8\nvar_sales_percentage_admin_2022_2c18f8ae = 3.1\nvar_sales_percentage_total_2022_2c18f8ae = 20.6\n\nvar_sales_percentage_sm_2023_2c18f8ae = 4.8\nvar_sales_percentage_rd_2023_2c18f8ae = 1.0\nvar_sales_percentage_admin_2023_2c18f8ae = 4.3\nvar_sales_percentage_total_2023_2c18f8ae = 20.8\n\nvar_sales_percentage_sm_2024_2c18f8ae = 12.6\nvar_sales_percentage_rd_2024_2c18f8ae = 3.7\nvar_sales_percentage_admin_2024_2c18f8ae = 4.3\nvar_sales_percentage_total_2024_2c18f8ae = 19.5\n\nvar_sales_percentage_sm_2025_2c18f8ae = 11.9\nvar_sales_percentage_rd_2025_2c18f8ae = 3.7\nvar_sales_percentage_admin_2025_2c18f8ae = 4.1\nvar_sales_percentage_total_2025_2c18f8ae = 17.6\n\n# Additional variables related to operational changes\nvar_inflation_rate_annual_2c18f8ae = 2.0  # Annual inflation rate for cost growth\nvar_additional_headcount_sm_2022_2c18f8ae = 5  # Additional S&M headcount in 2022\nvar_additional_headcount_sm_2023_2c18f8ae = 3  # Additional S&M headcount in 2023\nvar_additional_headcount_sm_2024_2c18f8ae = 1  # Additional S&M headcount in 2024\nvar_additional_headcount_sm_2025_2c18f8ae = 1  # Additional S&M headcount in 2025\nvar_additional_headcount_rd_annual_2c18f8ae = 1  # Additional R&D headcount added each year\nvar_additional_headcount_admin_annual_2c18f8ae = 1  # Additional Admin headcount added each year from 2022 to 2025\n\n# END OF CODE BLOCK 2c18f8ae\n\n```\n\nHere's the same data in Markdown format (if available):\n\n\n## END OF CODEBLOCK \n\n\n\n\n\n## START OF CODEBLOCK \nPy Filename: c:\\Users\\selhousseini\\Documents\\GitHub\\mm-doc-analysis-rag-ce\\doc_ingestion_aidan\\Intro_to_Aidian_Project_Atlas_15Jan2022.pdf\\text\\page_13.py\nPDF Filename: c:\\Users\\selhousseini\\Documents\\GitHub\\mm-doc-analysis-rag-ce\\doc_ingestion_aidan\\Intro_to_Aidian_Project_Atlas_15Jan2022.pdf\\Intro to Aidian Project Atlas 15Jan2022.pdf\nPDF Page: 13\n\nCode Block - Contents of the above Py file:\n```python\n\n# START OF CODE BLOCK c1add146\n\n# This code block captures the numerical data from a confidential document related to EW Healthcare Partners. \n# The document provides information about a non-binding bid, potential returns, trading updates, and sources & uses of funds.\n\n# Non-binding bid at an EV of c. \u20ac344M\nvar_bid_ev_euro_c1add146 = 344000000\n\n# Represents a 15x 2021E EBITDA of \u20ac22.9M\nvar_ebitda_multiple_c1add146 = 15\nvar_ebitda_2021_euro_c1add146 = 22900000\n\n# Assumes unitranche debt of \u20ac120M\nvar_unitranche_debt_euro_c1add146 = 120000000\n\n# Interest rate of 6.5% + EUROBOR\nvar_interest_rate_percentage_c1add146 = 6.5\n\n# Equity funding of \u20ac230M\nvar_equity_funding_euro_c1add146 = 230000000\n\n# Assumes MIP of 5%\nvar_mip_percentage_c1add146 = 5\n\n# Potential to generate 2.5x MOIC and IRR of 28%\nvar_potential_moic_c1add146 = 2.5\nvar_potential_irr_percentage_c1add146 = 28\n\n# END OF CODE BLOCK c1add146\n\n```\n\nHere's the same data in Markdown format (if available):\n\n| Variable Name | Value | Description |\n|---------------|-------|-------------|\n| var_bid_ev_euro_c1add146 | 344000000 | Non-binding bid at an EV of c. \u20ac344M |\n| var_ebitda_multiple_c1add146 | 15 | Represents a 15x 2021E EBITDA |\n| var_ebitda_2021_euro_c1add146 | 22900000 | 2021E EBITDA of \u20ac22.9M |\n| var_unitranche_debt_euro_c1add146 | 120000000 | Assumes unitranche debt of \u20ac120M |\n| var_interest_rate_percentage_c1add146 | 6.5 | Interest rate of 6.5% + EUROBOR |\n| var_equity_funding_euro_c1add146 | 230000000 | Equity funding of \u20ac230M |\n| var_mip_percentage_c1add146 | 5 | Assumes MIP of 5% |\n| var_potential_moic_c1add146 | 2.5 | Potential to generate 2.5x MOIC |\n| var_potential_irr_percentage_c1add146 | 28 | Potential to generate IRR of 28% |\n\n\n## END OF CODEBLOCK \n\n\n\n\n\n## START OF CODEBLOCK \nPy Filename: c:\\Users\\selhousseini\\Documents\\GitHub\\mm-doc-analysis-rag-ce\\doc_ingestion_aidan\\Intro_to_Aidian_Project_Atlas_15Jan2022.pdf\\text\\page_3.py\nPDF Filename: c:\\Users\\selhousseini\\Documents\\GitHub\\mm-doc-analysis-rag-ce\\doc_ingestion_aidan\\Intro_to_Aidian_Project_Atlas_15Jan2022.pdf\\Intro to Aidian Project Atlas 15Jan2022.pdf\nPDF Page: 3\n\nCode Block - Contents of the above Py file:\n```python\n\n# START OF CODE BLOCK acf00afa\n\n# The following variables represent numerical data extracted from an investment thesis for EW Healthcare Partners.\n# This data provides insights into market growth, financial profiles, and strategic opportunities for expansion and profitability.\n\n# var_market_growth_rate_acf00afa: The annual growth rate of the Point of Care (POC) In Vitro Diagnostics (IVD) market until 2025.\n# This rate is significant for projecting market size and potential revenue streams for companies operating in this segment.\nvar_market_growth_rate_acf00afa = 0.10\n\n# var_recurring_revenue_instruments_acf00afa: The number of installed instruments of the flagship QuickRead platform.\n# This number indicates the scale of the recurring revenue base and the market penetration of the product.\nvar_recurring_revenue_instruments_acf00afa = 60000\n\n# var_cash_conversion_rate_acf00afa: The percentage of cash conversion, indicating the efficiency of the company's operations\n# in turning profits into cash flow. A high rate suggests strong operational health and financial stability.\nvar_cash_conversion_rate_acf00afa = 0.90\n\n# var_potential_returns_multiple_acf00afa: The potential multiple of returns on investment within a hold period of 3-4 years.\n# This figure is used for investment appraisal and to set expectations for financial returns.\nvar_potential_returns_multiple_acf00afa = 2.5\n\n# var_hold_period_years_acf00afa: The expected hold period in years for the investment to potentially generate the targeted returns.\n# This duration is crucial for investment strategies and exit planning.\nvar_hold_period_years_acf00afa = 3.5  # Average of 3-4 years\n\n# var_mna_targets_acf00afa: The number of targets on the M&A shortlist, indicating the scope of potential acquisition opportunities.\n# This number helps in understanding the scale of expansion and strategic options available.\nvar_mna_targets_acf00afa = 80\n\n# END OF CODE BLOCK acf00afa\n\n```\n\nHere's the same data in Markdown format (if available):\n\n| Variable Name                             | Description                                                                                   | Value  |\n|-------------------------------------------|-----------------------------------------------------------------------------------------------|--------|\n| `var_market_growth_rate_acf00afa`         | Annual growth rate of the POC IVD market until 2025                                           | 0.10   |\n| `var_recurring_revenue_instruments_acf00afa` | Number of installed instruments of the flagship QuickRead platform                           | 60000  |\n| `var_cash_conversion_rate_acf00afa`      | Percentage of cash conversion indicating operational efficiency                               | 0.90   |\n| `var_potential_returns_multiple_acf00afa` | Potential multiple of returns on investment within a hold period of 3-4 years                | 2.5    |\n| `var_hold_period_years_acf00afa`         | Expected hold period in years for the investment                                              | 3.5    |\n| `var_mna_targets_acf00afa`               | Number of targets on the M&A shortlist                                                        | 80     |\n\n\n## END OF CODEBLOCK \n\n\n\n\n\n## START OF CODEBLOCK \nPy Filename: c:\\Users\\selhousseini\\Documents\\GitHub\\mm-doc-analysis-rag-ce\\doc_ingestion_aidan\\Intro_to_Aidian_Project_Atlas_15Jan2022.pdf\\text\\page_12.py\nPDF Filename: c:\\Users\\selhousseini\\Documents\\GitHub\\mm-doc-analysis-rag-ce\\doc_ingestion_aidan\\Intro_to_Aidian_Project_Atlas_15Jan2022.pdf\\Intro to Aidian Project Atlas 15Jan2022.pdf\nPDF Page: 12\n\nCode Block - Contents of the above Py file:\n```python\n\n```\n\nHere's the same data in Markdown format (if available):\n\n\n## END OF CODEBLOCK \n\n\n\n\n\n## START OF CODEBLOCK \nPy Filename: c:\\Users\\selhousseini\\Documents\\GitHub\\mm-doc-analysis-rag-ce\\doc_ingestion_aidan\\Intro_to_Aidian_Project_Atlas_15Jan2022.pdf\\text\\page_2.py\nPDF Filename: c:\\Users\\selhousseini\\Documents\\GitHub\\mm-doc-analysis-rag-ce\\doc_ingestion_aidan\\Intro_to_Aidian_Project_Atlas_15Jan2022.pdf\\Intro to Aidian Project Atlas 15Jan2022.pdf\nPDF Page: 2\n\nCode Block - Contents of the above Py file:\n```python\n\n# START OF CODE BLOCK b35c0b9b\n\n# This code block captures the financial and operational data of Aidian Oy, a Finland-based in-vitro diagnostics company. \n# The data includes expected sales, EBITDA, growth rate, and the indicative bid for the company. \n# The data is expected to be used for financial analysis and decision-making purposes.\n\n# Expected sales of Aidian Oy in 2021 in Euros\nvar_expected_sales_2021_b35c0b9b = 94.6e6 # Euros\n\n# EBITDA of Aidian Oy in 2021 in Euros\nvar_EBITDA_2021_b35c0b9b = 22.9e6 # Euros\n\n# Year-on-year growth rate of Aidian Oy in 2021\nvar_growth_rate_2021_b35c0b9b = 33 # Percentage\n\n# Indicative bid for Aidian Oy based on 2021E EBITDA\nvar_indicative_bid_b35c0b9b = 15 # Times EBITDA\n\n# Implied Enterprise Value of Aidian Oy based on the indicative bid\nvar_EV_b35c0b9b = 344e6 # Euros\n\n# Assumed debt financing for the acquisition of Aidian Oy\nvar_debt_financing_b35c0b9b = 120e6 # Euros\n\n# END OF CODE BLOCK b35c0b9b\n\n```\n\nHere's the same data in Markdown format (if available):\n\n\n## END OF CODEBLOCK \n\n\n\n\n\n## START OF CODEBLOCK \nPy Filename: c:\\Users\\selhousseini\\Documents\\GitHub\\mm-doc-analysis-rag-ce\\doc_ingestion_aidan\\Project_Atlas_-_CIM_-_pwd_Atlas2021.pdf\\text\\page_9.py\nPDF Filename: c:\\Users\\selhousseini\\Documents\\GitHub\\mm-doc-analysis-rag-ce\\doc_ingestion_aidan\\Project_Atlas_-_CIM_-_pwd_Atlas2021.pdf\\Project Atlas - CIM - pwd Atlas2021.pdf\nPDF Page: 9\n\nCode Block - Contents of the above Py file:\n```python\n\n# START OF CODE BLOCK 602e4651\n\n# The underlying non-cyclical POC IVD market is expected to grow by 10% year-on-year between 2021 and 2025.\nvar_market_growth_rate_602e4651 = 10\n\n# The installed base of QuikRead instruments sold worldwide is 60k.\nvar_quikread_instruments_sold_602e4651 = 60000\n\n# The direct sales model is used in 12 European countries, which accounts for 85% of sales.\nvar_direct_sales_countries_602e4651 = 12\nvar_direct_sales_percentage_602e4651 = 85\n\n# The distributor network enables a global reach in 70 countries.\nvar_distributor_network_countries_602e4651 = 70\n\n# The razorblade business model has approximately 90% recurring test revenue for the QuikRead platform.\nvar_recurring_test_revenue_percentage_602e4651 = 90\n\n# The gross margin and EBITDA margin for the QuikRead platform are approximately 45% and 20% respectively.\nvar_gross_margin_percentage_602e4651 = 45\nvar_EBITDA_margin_percentage_602e4651 = 20\n\n# The sales CAGR in direct sales markets since 2018 is 28%.\nvar_sales_CAGR_percentage_602e4651 = 28\n\n# END OF CODE BLOCK 602e4651\n\n```\n\nHere's the same data in Markdown format (if available):\n\n| Variable Name | Description |\n| --- | --- |\n| var_market_growth_rate_602e4651 | The underlying non-cyclical POC IVD market is expected to grow by 10% year-on-year between 2021 and 2025. |\n| var_quikread_instruments_sold_602e4651 | The installed base of QuikRead instruments sold worldwide is 60k. |\n| var_direct_sales_countries_602e4651 | The direct sales model is used in 12 European countries. |\n| var_direct_sales_percentage_602e4651 | The direct sales model accounts for 85% of sales. |\n| var_distributor_network_countries_602e4651 | The distributor network enables a global reach in 70 countries. |\n| var_recurring_test_revenue_percentage_602e4651 | The razorblade business model has approximately 90% recurring test revenue for the QuikRead platform. |\n| var_gross_margin_percentage_602e4651 | The gross margin for the QuikRead platform is approximately 45%. |\n| var_EBITDA_margin_percentage_602e4651 | The EBITDA margin for the QuikRead platform is approximately 20%. |\n| var_sales_CAGR_percentage_602e4651 | The sales CAGR in direct sales markets since 2018 is 28%. |\n\n\n## END OF CODEBLOCK \n\n\n\n\n\n## START OF CODEBLOCK \nPy Filename: c:\\Users\\selhousseini\\Documents\\GitHub\\mm-doc-analysis-rag-ce\\doc_ingestion_aidan\\Case_Study_#4_-_Comps.pdf\\tables\\page_1_table_0.py\nPDF Filename: c:\\Users\\selhousseini\\Documents\\GitHub\\mm-doc-analysis-rag-ce\\doc_ingestion_aidan\\Case_Study_#4_-_Comps.pdf\\Case Study #4 - Comps.pdf\nPDF Page: 1\n\nCode Block - Contents of the above Py file:\n```python\nimport pandas as pd\n\n# Unique dataframe name as per instructions\ndf_public_trading_comps_123456 = pd.DataFrame({\n    'Company Name': ['Roche', 'Abbott', 'Danaher', 'Becton, Dickinson', 'Sysmex', 'Hologic', 'Biomerieux', 'Diasorin', 'Tecan', 'Quidel', 'Ortho Clinical Diagnostics', 'Stratec', 'EKF Diagnostics', 'Mean', 'Median', 'Aidian - Mgmt Case'],\n    'Mkt Cap': ['\u20ac 281,994', '\u20ac 190,266', '\u20ac 176,695', '\u20ac 66,508', '\u20ac 18,204', '\u20ac 15,650', '\u20ac 12,035', '\u20ac 7,817', '\u20ac 5,497', '\u20ac 3,859', '\u20ac 3,754', '\u20ac 1,448', '\u20ac 400', '\u20ac', '\u20ac', '\u20ac'],\n    'EV': ['\u20ac 293,435', '\u20ac 198,132', '\u20ac 199,048', '\u20ac 80,427', '\u20ac 17,759', '\u20ac 17,397', '\u20ac 12,117', '\u20ac 8,973', '\u20ac 5,013', '\u20ac 3,474', '\u20ac 5,570', '\u20ac 1,492', '\u20ac 378', '\u20ac', '\u20ac', '\u20ac 99'],\n    'Revenue': ['\u20ac 56,648', '\u20ac 36,503', '\u20ac 24,209', '\u20ac 17,470', '\u20ac 2,643', '\u20ac 4,810', '\u20ac 3,216', '\u20ac 1,310', '\u20ac 798', '\u20ac 1,614', '\u20ac 1,758', '\u20ac 296', '\u20ac 90', '\u20ac', '\u20ac', '\u20ac'],\n    'Revenue CAGR 18-21E': ['4.4%', '11.6%', '20.0%', '3.9%', '3.8%', '13.5%', '11.4%', '22.2%', '20.2%', '44.4%', '4.8%', '15.3%', '25.0%', '15.4%', '13.5%', '20.8%'],\n    'Revenue CAGR 21-23E': ['2.1%', '10.0%', '5.8%', '4.7%', '3.2%', '7.2%', '2.8%', '6.7%', '8.2%', '33.0%', '8.3%', '8.2%', '3.9%', '1.3%', '3.4%', '9.5%'],\n    'Gross Margin': ['72.3%', '56.8%', '60.7%', '47.8%', '51.7%', '72.3%', '67.5%', '50.6%', '49.5%', '79.3%', '24.4%', '29.7%', '32.2%', '57.1%', '56.8%', '42.7%'],\n    'EBITDA Margin': ['37.6%', '28.2%', '34.4%', '27.9%', '27.0%', '51.3%', '27.7%', '23.0%', '22.4%', '34.3%', '12.4%', '22.4%', '32.4%', '34.1%', '29.2%', '23.1%'],\n    'LTM': ['12.8x', '17.7x', '22.7x', '15.8x', '25.9x', '6.8x', '13.2x', '18.5x', '25.1x', '3.5x', '11.8x', '21.8x', '12.4x', '17.1x', '16.7x', '15.0x'],\n    'NTM': ['11.8x', '19.1x', '22.0x', '16.6x', '22.3x', '13.9x', '13.2x', '19.2x', '22.4x', '7.0x', '11.6x', '19.8x', '12.1x', '17.0x', '17.9x', '12.7x'],\n    '23E': ['11.2x', '17.8x', '20.4x', '15.2x', '19.7x', '13.4x', '13.7x', '19.2x', '19.2x', '23.0x', '10.6x', '17.9x', '11.3x', '15.8x', '16.5x', '11.8x'],\n    'Cash Conv.': ['84.3%', '84.3%', '87.7%', '78.2%', '89.2%', '94.6%', '67.1%', '95.3%', '85.4%', '75.9%', '91.3%', '81.7%', '92.9%', '85.2%', '85.4%', '96.1%'],\n    'LFCF Yield LTM': ['5.3%', '3.3%', '3.3%', '5.6%', '4.3%', '9.6%', '2.1%', '4.5%', '3.1%', '14.7%', '7.8%', '2.3%', '2.8%', '4.3%', '4.4%', '4.0%']\n})\n\n# Display the dataframe\nprint(df_public_trading_comps_123456)\n```\n\nHere's the same data in Markdown format (if available):\n\n| Company Name         | Mkt Cap | EV     | Revenue | Revenue CAGR | LTM Margin % | EV/EBITDA | Cash Conv. | LFCF Yield |\n|----------------------|---------|--------|---------|--------------|--------------|-----------|-------------|------------|\n|                      |         |        | 18'-21E | 21E-23E Gross| LTM  | NTM  | LTM  | LTM         | LTM         |\n|                      | (\u20ac m)   | (\u20ac m)  | (\u20ac m)   |              | Gross| EBITDA| 23E  |             |             |\n| Roche                | 281,994 | 293,435| 56,648  | 4.4%         | 72.3%| 37.6% | 12.8x| 11.8x       | 5.3%        |\n| Abbott               | 190,266 | 198,132| 36,503  | 11.6%        | 58.6%| 28.2% | 17.7x| 19.1x       | 5.3%        |\n| Danaher              | 176,695 | 199,048| 24,209  | 20.0%        | 60.7%| 34.4% | 22.7x| 22.0x       | 3.3%        |\n| Becton, Dickinson    | 66,508  | 80,427 | 17,470  | 3.9%         | 48.7%| 27.9% | 15.8x| 16.6x       | 5.6%        |\n| Sysmex               | 18,204  | 17,759 | 2,643   | 3.8%         | 51.7%| 27.0% | 25.9x| 22.3x       | 4.3%        |\n| Hologic              | 15,650  | 17,397 | 4,810   | 13.5%        | 72.3%| 51.3% | 6.8x | 13.9x       | 9.6%        |\n| Biomerieux           | 12,035  | 12,117 | 3,316   | 11.4%        | 67.5%| 27.7% | 13.2x| 13.2x       | 2.1%        |\n| Diasorin             | 7,817   | 8,973  | 1,210   | 22.2%        | 80.6%| 43.0% | 18.8x| 19.1x       | 4.5%        |\n| Tecan                | 5,497   | 5,013  | 798     | 20.2%        | 49.5%| 22.4% | 25.1x| 22.4x       | 3.1%        |\n| Quidel               | 3,859   | 3,474  | 1,614   | 44.4%        | 79.3%| 64.3% | 3.5x | 7.0x        | 14.7%        |\n| Ortho Clinical Diagnostics | 3,754 | 5,570 | 1,758 | 4.8%       | 49.1%| 24.2% | 11.8x| 11.6x       | 7.8%        |\n| Stratec              | 1,448   | 1,492  | 296     | 15.3%        | 52.8%| 22.4% | 21.8x| 19.8x       | 2.3%        |\n| EKF Diagnostics      | 400     | 378    | 90      | 25.0%        | 53.9%| 32.2% | 12.4x| 12.1x       | 2.8%        |\n| **Mean**             |         |        |         | 15.4%        | 57.3%| 34.1% | 17.1x| 17.0x       | 4.3%        |\n| **Median**           |         |        |         | 13.5%        | 54.6%| 28.9% | 16.7x| 17.9x       | 4.4%        |\n| **Aidian - Mgmt Case** |       |        |         | 20.8%        | 42.7%| 23.1% | 15.0x| 12.7x       | 4.0%        |\n\n\n## END OF CODEBLOCK \n\n\n\n\n\n## START OF CODEBLOCK \nPy Filename: c:\\Users\\selhousseini\\Documents\\GitHub\\mm-doc-analysis-rag-ce\\doc_ingestion_aidan\\Case_Study_#4_-_Comps.pdf\\images\\page_1_image_2.py\nPDF Filename: c:\\Users\\selhousseini\\Documents\\GitHub\\mm-doc-analysis-rag-ce\\doc_ingestion_aidan\\Case_Study_#4_-_Comps.pdf\\Case Study #4 - Comps.pdf\nPDF Page: 1\n\nCode Block - Contents of the above Py file:\n```python\n\nimport pandas as pd\n\ndata = {\n    'Company Name': ['Roche', 'Abbott', 'Danaher', 'Becton, Dickinson', 'Sysmex', 'Hologic', 'Biomerieux', 'Diasorin', 'Tecan', 'Quidel', 'Ortho Clinical Diagnostics', 'Stratec', 'EKF Diagnostics', 'Mean', 'Median', 'Aidian - Mgmt Case'],\n    'Mkt Cap': ['\u20ac281,994', '\u20ac190,266', '\u20ac176,695', '\u20ac66,508', '\u20ac18,204', '\u20ac15,650', '\u20ac12,035', '\u20ac7,817', '\u20ac5,497', '\u20ac3,859', '\u20ac3,754', '\u20ac1,448', '\u20ac400', '', '', ''],\n    'EV': ['\u20ac293,435', '\u20ac198,132', '\u20ac199,048', '\u20ac80,427', '\u20ac17,759', '\u20ac17,397', '\u20ac12,117', '\u20ac8,973', '\u20ac5,013', '\u20ac3,474', '\u20ac5,570', '\u20ac1,492', '\u20ac378', '', '', ''],\n    'Revenue': ['\u20ac56,648', '\u20ac36,503', '\u20ac24,209', '\u20ac17,470', '\u20ac2,643', '\u20ac4,810', '\u20ac3,126', '\u20ac1,310', '\u20ac798', '\u20ac1,614', '\u20ac1,758', '\u20ac296', '\u20ac90', '', '', '99'],\n    # ... (other columns follow the same pattern)\n}\n\ndf_public_trading_comps_3927364 = pd.DataFrame(data)\n\n```\n\nHere's the same data in Markdown format (if available):\n\n| Company Name                | Mkt Cap | EV     | Revenue | Revenue CAGR 18'-21'E | Revenue CAGR 21'E-23'E | LTM Margin % Gross | LTM Margin % EBITDA | EV/EBITDA LTM | EV/EBITDA NTM | EV/EBITDA 23E | Cash Conv. LFCF Yield LTM | Cash Conv. LFCF Yield LTM |\n|-----------------------------|---------|--------|---------|-----------------------|------------------------|--------------------|---------------------|---------------|---------------|---------------|---------------------------|---------------------------|\n| Roche                       | \u20ac281,994| \u20ac293,435| \u20ac56,648 | 4.4%                  | 72.3%                  | 37.6%              | 12.8x               | 11.8x         | 11.2x         | 84.3%                     | 5.3%                      |\n| Abbott                      | \u20ac190,266| \u20ac198,132| \u20ac36,503 | 11.6%                 | 56.8%                  | 29.5%              | 17.7x               | 19.1x         | 17.8x         | 84.3%                     | 5.3%                      |\n| ...                         | ...     | ...    | ...     | ...                   | ...                    | ...                | ...                 | ...           | ...           | ...                       | ...                       |\n| Mean                        |         |        |         | 15.4%                 | 57.3%                  | 34.1%              | 17.1x               | 17.0x         | 15.8x         | 85.2%                     | 4.3%                      |\n| Median                      |         |        |         | 13.5%                 | 54.6%                  | 29.2%              | 16.7x               | 17.9x         | 16.5x         | 85.4%                     | 4.4%                      |\n| Aidian - Mgmt Case          |         |        | 99      | 20.8%                 | 9.5%                   | 42.7%              | 23.1%               | 15.0x         | 12.7x         | 11.8x                     | 96.1%                     | 4.0%                      |\n\n\n## END OF CODEBLOCK \n\n\n\n\n\n## START OF CODEBLOCK \nPy Filename: c:\\Users\\selhousseini\\Documents\\GitHub\\mm-doc-analysis-rag-ce\\doc_ingestion_aidan\\Case_Study_#4_-_Comps.pdf\\text\\page_1.py\nPDF Filename: c:\\Users\\selhousseini\\Documents\\GitHub\\mm-doc-analysis-rag-ce\\doc_ingestion_aidan\\Case_Study_#4_-_Comps.pdf\\Case Study #4 - Comps.pdf\nPDF Page: 1\n\nCode Block - Contents of the above Py file:\n```python\n\n# START OF CODE BLOCK d5e28541\n\n# There are no numerical quantities in the TEXT EXTRACT to declare as variables.\n\n# END OF CODE BLOCK d5e28541\n\n```\n\nHere's the same data in Markdown format (if available):\n\nThere are no numerical data quantities in the TEXT EXTRACT to represent in a Markdown table.\n\n\n## END OF CODEBLOCK \n\n\n\n\n\n## START OF CODEBLOCK \nPy Filename: c:\\Users\\selhousseini\\Documents\\GitHub\\mm-doc-analysis-rag-ce\\doc_ingestion_aidan\\Case_Study_#4_-_Comps.pdf\\text\\page_2.py\nPDF Filename: c:\\Users\\selhousseini\\Documents\\GitHub\\mm-doc-analysis-rag-ce\\doc_ingestion_aidan\\Case_Study_#4_-_Comps.pdf\\Case Study #4 - Comps.pdf\nPDF Page: 2\n\nCode Block - Contents of the above Py file:\n```python\n\n```\n\nHere's the same data in Markdown format (if available):\n\n\n## END OF CODEBLOCK \n\n\n\n\n\n## START OF CODEBLOCK \nPy Filename: c:\\Users\\selhousseini\\Documents\\GitHub\\mm-doc-analysis-rag-ce\\doc_ingestion_aidan\\Project_Atlas_-_CIM_-_pwd_Atlas2021.pdf\\text\\page_106.py\nPDF Filename: c:\\Users\\selhousseini\\Documents\\GitHub\\mm-doc-analysis-rag-ce\\doc_ingestion_aidan\\Project_Atlas_-_CIM_-_pwd_Atlas2021.pdf\\Project Atlas - CIM - pwd Atlas2021.pdf\nPDF Page: 106\n\nCode Block - Contents of the above Py file:\n```python\n\n# START OF CODE BLOCK 1d4a9fee\n\n# This code block contains variables that capture key numerical data points from a confidential text extract\n# regarding the monetisation strategies for the SIBA technology platform. The variables are intended to be used\n# by other Python programs that may need to reference or analyze these strategies and their potential impacts.\n# The text extract discusses various pathways for monetisation, including outlicensing, co-development, point-of-care\n# (POC) medical diagnostics (MDx) strategy, and instrument-free SIBA development. It also mentions the potential\n# for entering the US market, leveraging existing customer groups, and building an intellectual property (IP) portfolio.\n# The extract includes an executive summary that covers market overview, product portfolio, group operations,\n# strategic growth levers, financial overview, and conclusions. Additionally, it touches on cost optimisation,\n# mergers and acquisitions (M&A), US expansion, organic growth, China market, the SIBA platform, and EW Healthcare.\n\n# Note: The TEXT EXTRACT does not contain explicit numerical data. Therefore, no variables are declared.\n# The following is a placeholder for the structure of the code block in case numerical data were present.\n\n# Example of a variable declaration if numerical data were present:\n# var_example_numerical_data_1d4a9fee = 0  # This variable would represent an example numerical data point from the text extract.\n\n# END OF CODE BLOCK 1d4a9fee\n\n```\n\nHere's the same data in Markdown format (if available):\n\n| Variable Name | Purpose | Context | Source |\n|---------------|---------|---------|--------|\n|               |         |         |        |\n\n\n## END OF CODEBLOCK \n\n\n\n\nDo **NOT** forget to import the below py modules in every new code block you generate:\n# Import the list of Python files specified by the user\nList of Python Files:\n## START OF LIST OF PYTHON FILES TO IMPORT\n\n## END OF LIST OF PYTHON FILES TO IMPORT\n\nHere is the Chain of Thought and the step-by-step that you should follow:\n\n    1. Please analyze the question first, and locate the variables of interests in the question. For each variable, try to locate the relevant dataframes in the Codeblocks above (delimited by '## START OF CODEBLOCK' and '## END OF CODEBLOCK') and the relevant variable assignment statements.\n    2. You **MUST** import the list of Python files specified by the user above in the \"List of Python Files\" section.\n    3. Use the Codeblocks delimited by '## START OF CODEBLOCK' and '## END OF CODEBLOCK' to identify and print to the output the variables of interest. Include the variable assignment statements in the output. Limit this list to the relevant variables **ONLY**. Generate the Python code that will do this step and execute it.\n    4. Use the Codeblocks delimited by '## START OF CODEBLOCK' and '## END OF CODEBLOCK' to identify and print to the output the relevant dataframes names, and print to the output all their columns. Also print all the variable assignment statements. Include the dataframes assignment statements in the output. Limit this list to the relevant dataframes **ONLY**. Generate the Python code that will do this step and execute it.\n    5. If you have trouble accessing the previously defined variables or the dataframes for any reasons, then use the Python Codeblocks delimited by '## START OF CODEBLOCK' and '## END OF CODEBLOCK' to extract the information you need, and then generate the needed Python code.\n    6. Generate the answer to the query. You **MUST** clarify AND print to the output **ALL** calculation steps leading up to the final answer.\n    7. You **MUST** detail how you came up with the answer. Please provide a complete description of the calculation steps taken to get to the answer. Please reference the PDF Document and the page number you got the answer from, e.g. \"This answer was derived from document 'Sales_Presentation.pdf', page 34\".\n    8. If the answer contains numerical data, then you **MUST** create an Excel file with an extension .xlsx with the data, you **MUST** include inside the Excel the steps of the calculations, the justification, and **ALL** the reference and source numbers and tables that you used to come up with a final answer in addition to the final answer (this Excel is meant for human consumption, do **NOT** use programming variable names as column or row headers, instead use names that are fully meaningful to humans), you **MUST** be elaborate in your comments and rows and column names inside the Excel, you **MUST** save it to the working directory, and then you **MUST** print the full path of the Excel sheet with the final answer - use os.path.abs() to print the full path.\n    9. **VERY IMPORTANT**: do **NOT** attempt to create a list of variables or dataframes directly. Instead, you should access the data from the variables and dataframes that were defined in the Python file that was run.\n    \n\nQuestion: is it good option to invest in this company?\n\nIn your final answer, be elaborate in your response. Describe your logic and the calculation steps to the user, and describe how you deduced the answer step by step. If there are any assumptions you made, please state them clearly. Describe in details the computation steps you took, quote values and quantities, describe equations as if you are explaining a solution of a math problem to a 12-year old student. Please relay all steps to the user, and clarify how you got to the final answer. Please reference the PDF Document and the page number you got the answer from, e.g. \"This answer was derived from document 'Sales_Presentation.pdf', page 34\". After generating the final response, and if the final answer contains numerical data, then you **MUST** create an Excel file with an extension .xlsx with the data, you **MUST** include inside the Excel the steps of the calculations, the justification, and **ALL** the reference and source numbers and tables that you used to come up with a final answer in addition to the final answer (this Excel is meant for human consumption, do **NOT** use programming variable names as column or row headers, instead use names that are fully meaningful to humans), you **MUST** be elaborate in your comments and rows and column names inside the Excel, you **MUST** save it to the working directory, and then you **MUST** print the full path of the Excel sheet with the final answer - use os.path.abs() to print the full path.\n\n", "send_from": "User", "send_to": "Planner", "attachment_list": []}]}